Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses

Human Gene Therapy

Volumn 17, Issue 9, 2006, Pages 929-940

  Cascallo, Manel ^a   Gros, Alena ^a   Bayo, Neus ^a   Serrano, Teresa ^b   Capella, Gabriel ^a   Alemany, Ramon ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADSUB719; ADVADEL; ONCOLYTIC ADENOVIRUS; RAS PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; RNA GENE; RNA TRANSLATION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS ASSEMBLY; VIRUS MUTANT; VIRUS REPLICATION; ADENOVIRUS; CELL LINE; GENETICS; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS GENE;

ADENOVIRIDAE;

ADENOVIRIDAE; BASE SEQUENCE; CELL LINE; DNA PRIMERS; GENES, VIRAL; HUMANS; MUTATION; NEOPLASMS; VIRUS REPLICATION;

EID: 33750607468     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.929     Document Type: Article

References (39)

1. ALEMANY, R., BALAGUE, C., and CURIEL, D.T. (2000). Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723-727.
2. BERGMANN, M., ROMIRER, I., SACHET, M., FLEISCHHACKER, R., GARCIA-SASTRE, A., PALESE, P., WOLFF, K., PEHAMBERGER, H., JAKESZ, R., and MUSTER, T. (2001). A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 61, 8188-8193.
3. BHAT, R.A., and THIMMAPPAYA, B. (1984). Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells. Nucleic Acids Res. 12, 7377-7388.
4. CASCALLO, M., and ALEMANY, R. (2004). Adenovirus-mediated gene transfer to tumor cells. Methods Mol. Biol. 246, 121-138.
5. CASCALLO, M., CAPELLA, G., MAZO, A., and ALEMANY, R. (2003). Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res. 63, 5544-5550.
6. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
7. CHU, R.L., POST, D.E., KHURI, F.R., and VAN MEIR, E.G. (2004). Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 10, 5299-5312.
8. CLEMENS, M.J., and BOMMER, U.A. (1999). Translational control: The cancer connection. Int. J. Biochem. Cell Biol. 31, 1-23.
9. DE ROOIJ, J., and BOS, J.L. (1997). Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14, 623-625.
10. FARASSATI, F., YANG, A.D., and LEE, P.W. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745-750.
11. FOWLKES, D.M., and SHENK, T. (1980). Transcriptional control regions of the adenovirus VAI RNA gene. Cell 22, 405-413.
12. FURTADO, M.R., SUBRAMANIAN, S., BHAT, R.A., FOWLKES, D.M., SAFER, B., and THIMMAPPAYA, B. (1989). Functional dissection of adenovirus VAI RNA. J. Virol. 63, 3423-3434.
13. GHADGE, G.D., SWAMINATHAN, S., KATZE, M.G., and THIMMAPAYA, B. (1991). Binding of the adenovirus VAI RNA to the interferon-induced 68-kDa protein kinase correlates with function. Proc. Natl. Acad. Sci. U.S.A. 88, 7140-7144.
14. GIEDLIN, M.A., COOK, D.N., and DUBENSKY, T.W., Jr. (2003). Vesicular stomatitis virus: An exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology? Cancer Cell 4, 241-243.
15. GOMEZ-LECHON, M.J., LOPEZ, P., DONATO, T., MONTOYA, A., LARRAURI, A., GIMENEZ, P., TRULLENQUE, R., FABRA, R., and CASTELL, J.V. (1990). Culture of human hepatocytes from small surgical liver biopsies: Biochemical characterization and comparison in vivo. In Vitro Cell Dev. Biol. 26, 67-74.
16. GOODBOURN, S., DIDCOCK, L., and RANDALL, R.E. (2000). Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81, 2341-2364.
17. GRANDER, D., and EINHORN, S. (1998). Interferon and malignant disease: How does it work and why doesn't it always? Acta Oncol. 37, 331-338.
18. GUILFOYLE, R., and WEINMANN, R. (1981). Control region for adenovirus VA RNA transcription. Proc. Natl. Acad. Sci. U.S.A. 78, 3378-3382.
19. HAMID, O., VARTERASIAN, M.L., WADLER, S., HECHT, J.R., BENSON, A., III, GALANIS, E., UPRICHARD, M., OMER, C., BYCOTT, P., HACKMAN, R.C., and SHIELDS, A.F. (2003). Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 1498-1504.
20. r protein kinase to regulate its autophosphorylation and activity. EMBO J. 6, 689-697.
21. MA, Y., and MATHEWS, M.B. (1993). Comparative analysis of the structure and function of adenovirus virus-associated RNAs. J. Virol. 67, 6605-6617.
22. MA, Y., and MATHEWS, M.B. (1996). Structure, function, and evolution of adenovirus-associated RNA: A phylogenetic approach. J. Virol. 70, 5083-5099.
23. MORI, K.-I., JUTTERMANN, R., WIENHUES, U., KOBAYASHI, K., YAGI, M., SUGIMOTO, T., TJIA, S.T., DOERFLER, W., and HOSOKAWA, K. (1996). Anti-interferon activity of adenovirus-2-encoded VAI and VAII RNAs in translation in cultured human cells. Virus Res. 42, 53-63.
24. MUNDSCHAU, L.J., and FALLER, D.V. (1992). Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2a-kinase activation. J. Biol. Chem. 267, 23092-23098.
25. NEMUNAITIS, J., CUNNINGHAM, C., BUCHANAN, A., BLACKBURN, A., EDELMAN, G., MAPLES, P., NETTO, G., TONG, A., RANDLEV, B., OLSON, S., and KIRN, D. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther. 8, 746-759.
26. O'MALLEY, R.P., MARIANO, T.M., SIEKIERKA, J., and MATHEWS, M.B. (1986). A mechanism for the control of protein synthesis by adenovirus VA RNAI. Cell 44, 391-400.
27. SARINELLA, F., CALISTRI, A., SETTE, P., PALU, G., and PAROLIN, C. (2006). Oncolysis of pancreatic tumour cells by a γ34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther. 13, 1080-1087.
28. SCHNEIDER, R.J., WEINBERGER, C., and SHENK, T. (1984). Adenovirus VAI RNA facilitates the initiation of translation in virus-infected cells. Cell 37, 291-298.
29. SCHUMANN, M., and DOBBELSTEIN, M. (2006a). Activating Ras mutations fail to ensure efficient replication of adenovirus mutants lacking VA-RNA. Cell Cycle 5, 315-321.
30. SCHUMANN, M., and DOBBELSTEIN, M. (2006b). Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny. Cancer Res. 66, 1282-1288.
31. SODERLUND, H., PETTERSSON, U., VENNSTROM, B., PHILIPSON, L., and MATHEWS, M.B. (1976). A new species of virus-coded low molecular weight RNA from cells infected with adenovirus type 2. Cell 7, 585-593.
32. STRONG, J.E., COFFEY, M.C., TANG, D., SABININ, P., and LEE, P.W. (1998). The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351-3362.
33. SUBRAMANIAN, S., BHAT, R.A., RUNDELL, M.K., and THIMMAPPAYA, B. (1986). Suppression of the translation defect phenotype specific for a virus-associated RNA-deficient adenovirus mutant in monkey cells by simian virus 40. J. Virol. 60, 363-368.
34. SWAMINATHAN, S., RAJAN, P., SAVINOVA, O., JAGUS, R., and THIMMAPAYA, B. (1996). Simian virus 40 large-T bypasses the translational block imposed by the phosphorylation of eIF-2α. Virology 219, 321-323.
35. THIMMAPPAYA, B., WEINBERGER, C., SCHNEIDER, R.J., and SHENK, T. (1982). Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 31, 543-551.
36. VILLANUEVA, A., GARCIA, C., PAULES, A.B., VICENTE, M., MEGIAS, M., REYES, G., DE VILLALONGA, P., AGELL, N., LLUIS, F., BACHS, O., and CAPELLA, G. (1998). Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17, 1969-1978.
37. WANG, Y., XUE, S.A., HALLDEN, G., FRANCIS, J., YUAN, M., GRIFFIN, B.E., and LEMOINE, N.R. (2005). Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res. 65, 1523-1531.
38. WILLIAMS, B.R. (1999). PKR: A sentinel kinase for cellular stress. Oncogene 18, 6112-6120.
39. WORKING, P.K., LIN, A., and BORELLINI, F. (2005). Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 24, 7792-7801.